Table 3.
Effect of the dsDNA to DNase activity ratio measured at the peripheral site on cardiovascular and all-cause mortality of STEMI patients at long-term follow-up
| Factor | Cardiovascular mortality | All-cause mortality | ||||
|---|---|---|---|---|---|---|
| Adjusted HR | 95% CI | p-value | Adjusted HR | 95% | p-value | |
| Age | 1.10 | 1.03–1.18 | 0.003 | 1.01 | 1.05–1.14 | < 0.0001 |
| Male sex | 0.47 | 0.92–2.37 | 0.357 | 1.26 | 0.49–3.22 | 0.635 |
| BMI | 0.89 | 0.76–1.05 | 0.179 | 0.95 | 0.86–1.06 | 0.374 |
| Hyperlipidemia | 0.43 | 0.12–1.58 | 0.204 | 0.79 | 0.33–1.89 | 0.600 |
| Arterial hypertension | 0.38 | 0.10–1.47 | 0.162 | 0.26 | 0.11–0.63 | 0.003 |
| Diabetes mellitus | 4.84 | 1.30–18.07 | 0.019 | 2.19 | 0.80–6.04 | 0.128 |
| Ever smoker | 1.13 | 0.28–4.56 | 0.863 | 1.72 | 0.67–4.47 | 0.262 |
| Creatinine on admission | 4.02 | 1.63–9.89 | 0.003 | 2.94 | 1.43–6.05 | 0.003 |
| dsDNA/DNase activity ratio | 1.28 | 1.05–1.57 | 0.016 | 1.25 | 1.05–1.48 | 0.012 |
Multivariable Cox regression was used to assess the influence of a homozygous SNP in the Q222R DNase 1 gene on cardiovascular and all-cause mortality, after a median follow-up of 60.0 [IQR 30.3, 91.5] months
BMI body mass index, CI confidence interval, DNase deoxyribonuclease, dsDNA double-stranded DNA, HR hazard ratio, IQR interquartile range, SNP single nucleotide polymorphism, STEMI ST-segment elevation myocardial infarction.